Sanofi NASDAQ: SNY is advancing a slate of vaccine candidates targeting respiratory infections, pneumococcal disease and acne, with several clinical readouts expected over the next 18 months, according to its head of vaccines research and development.
Jean-François Toussaint said the company recently began a phase III immunogenicity study of a combined flu and COVID-19 vaccine and expects results within that period. Sanofi also expects results from pediatric phase III trials of its 21-component pneumococcal conjugate vaccine in 2027.
The programs are part of a vaccine pipeline that Toussaint said has been prioritized over several years. He said vaccines remain an important growth driver under CEO Belén Garijo, alongside immunology and inflammation and rare diseases.
Respiratory and pneumococcal programs
Toussaint described the flu-COVID combination as a potential growth driver, combining Sanofi’s flu vaccine with a COVID vaccine from Novavax. He said the company is also developing a combined vaccine for respiratory syncytial virus, or RSV, and human metapneumovirus, or hMPV.
Sanofi has two RSV-hMPV candidates: one based on messenger RNA and another acquired through Vicebio. Toussaint said the Vicebio candidate is designed to be stored as a liquid in a prefilled syringe in a refrigerator, and the company expects it to allow a boosted immune response. He cautioned that Sanofi does not yet have all the data needed to decide which approach is best.
The company has started a phase IIb study of an RSV-hMPV candidate to monitor efficacy and assess a suitable endpoint for hMPV before a potentially expensive phase III trial. Toussaint said he hopes to have data in about 18 months, though he was unsure whether the company would share the results publicly.
For its pneumococcal candidate, known as PCV21, Sanofi has six phase III trials underway in children. Toussaint said the company is not counting on a preferential recommendation over existing vaccines based on the number of components alone. Instead, he pointed to Sanofi’s pediatric vaccine portfolio and commercial scale as potential advantages in winning market share if the candidate succeeds.
Acne vaccine and broader research
Sanofi has expanded a phase II trial of its acne vaccine candidate to 800 volunteers from an initial 200. Toussaint said the larger study should provide a more robust indication of whether the vaccine works and whether it benefits particular patient groups. He pointed to 2028 for results.
The candidate aims to neutralize bacteria and the toxin they produce to limit inflammation, Toussaint said. Beyond acne, he said a positive result could provide proof of concept for developing vaccines against other pathogens that trigger inflammation.
Sanofi also obtained an experimental shingles vaccine through its Dynavax deal. Toussaint said the candidate has produced good data in younger adults, but the company needs to see results in older adults before determining its path forward.
Pipeline priorities and partnerships
Toussaint said Sanofi previously discontinued an mRNA flu vaccine program despite results comparable to competitors because the company did not believe the technology would make a difference in that market. Vaccine pipeline prioritization remains an ongoing process, he said.
Asked about cancer vaccines following melanoma data from Moderna, Toussaint said Sanofi has an mRNA platform that could potentially be used in the field, but that he was not convinced the company would pursue cancer vaccines itself. He said providing access to the platform to another developer could be an option.
Toussaint also discussed Beyfortus, the RSV antibody product Sanofi co-developed with AstraZeneca. He said both maternal immunization and monoclonal antibodies can reduce hospitalization risk, but argued that the antibody approach offers longer-lasting protection and more flexibility in timing administration for infants.
About Sanofi (NASDAQ:SNY)
Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company's portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.